SCHEMBL6299373

SCHEMBL6299373

CC(C)(C)c1cc(O)c(Cc2c(O)cc(C(C)(C)C)cc2C(C)(C)C)c(C(C)(C)C)c1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.44
ALOX15 P16050 4/20 0.44
SMN1; SMN2 Q16637 4/20 0.44
CYP1A2 P05177 2/20 0.44
MAPT P10636 2/20 0.44
KDM4E B2RXH2 1/20 0.44
ATP2A2 P16615 1/20 0.44
ATP2A3 Q93084 1/20 0.44
HSD17B10 Q99714 2/20 0.43
TDP1 Q9NUW8 2/20 0.43
HPGD P15428 2/20 0.43
GABRA1 P14867 1/20 0.43
GABRB2 P47870 1/20 0.43
CYP2C9 P11712 4/20 0.42
CYP2C19 P33261 4/20 0.42
HIF1A Q16665 2/20 0.42
TP53 P04637 2/20 0.42
TSHR P16473 2/20 0.39
CYP3A4 P08684 2/20 0.39
TYR P14679 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27877809 0.86 ALDH1A1 (0.43) ALDH1A1ALOX15SMN1; SMN2CYP1A2MAPT
SCHEMBL3616927 0.85 ALDH1A1 (0.39) ALDH1A1ALOX15SMN1; SMN2CYP1A2MAPT
SCHEMBL292111 0.84 LMNA (0.42) ALDH1A1ALOX15CYP1A2HSD17B10TDP1
SCHEMBL11681295 0.84 TSHR (0.46) ALDH1A1ALOX15CYP1A2KDM4EHSD17B10
SCHEMBL1159884 0.84 ALDH1A1 (0.41) ALDH1A1ALOX15SMN1; SMN2CYP1A2MAPT
SCHEMBL29450175 0.84 ALDH1A1 (0.41) ALDH1A1ALOX15SMN1; SMN2CYP1A2MAPT
SCHEMBL30438699 0.82 ALDH1A1 (0.40) ALDH1A1ALOX15SMN1; SMN2CYP1A2MAPT
Hydrochloric Acid SCHEMBL3624760 0.82 ALDH1A1 (0.40) ALDH1A1ALOX15SMN1; SMN2CYP1A2MAPT
SCHEMBL3626563 0.81 HTR1D (0.56) ALDH1A1ALOX15SMN1; SMN2CYP1A2MAPT
SCHEMBL27818403 0.80 HPGD (0.50) ALDH1A1ALOX15SMN1; SMN2CYP1A2MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6841694-B2 Process for stabilizing unsaturated organosilicon compounds WACKER-CHEMIE GMBH (DE) 2005-01-11 US disclosed
EP-1469002-A1 Method for stabilizing unsaturated organo-silicon compounds Wacker-Chemie GmbH (DE) 2004-10-20 EP disclosed
US-20040171859-A1 Process for stabilizing unsaturated organosilicon compounds WACKER-CHEMIE GMBH (DE) 2004-09-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040171859-A1 Process for stabilizing unsaturated organosilicon compounds ELOVL1, ELOVL6, DEGS1 ALDH1A1 402/4885ALOX15 8/4885SMN1; SMN2 1421/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.